Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experience with multiagent chemotherapy for osteosarcoma. Improved outcome.

A M Goorin1, J W Andersen

  • 1Department of Hematology/Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115.

Clinical Orthopaedics and Related Research
|September 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dietary supplementation of male mice with inorganic, organic or nanoparticle selenium preparations: evidence supporting a putative gut-thyroid-male fertility axis.

Redox report : communications in free radical research·2025
Same author

Use of point-of-care HbA<sub>1c</sub> measurement to estimate the level of undiagnosed diabetes mellitus among 67-year-old participants in a cardiovascular screening programme in the municipality of Viborg, Denmark.

Diabetic medicine : a journal of the British Diabetic Association·2018
Same author

Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 study.

Journal of viral hepatitis·2012
Same author

The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin.

Alimentary pharmacology & therapeutics·2011
Same author

Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial.

Journal of pediatric hematology/oncology·2001
Same author

Current treatment of osteosarcoma.

Cancer investigation·2001

Adjuvant chemotherapy significantly improves disease-free survival for osteosarcoma patients. Limb-salvage surgery offers comparable outcomes to amputation, indicating improved treatment efficacy and patient options.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Chemotherapy

Background:

  • Osteosarcoma treatment has evolved significantly since 1972.
  • Adjuvant chemotherapy and limb-salvage surgery are key treatment modalities.
  • Long-term clinical data collection is crucial for evaluating treatment efficacy.

Purpose of the Study:

  • To evaluate the impact of adjuvant chemotherapy on disease-free survival (DFS) in osteosarcoma.
  • To compare the outcomes of limb-salvage surgery versus amputation in osteosarcoma patients.
  • To assess the long-term efficacy of multiagent, alternating adjuvant chemotherapy.

Main Methods:

  • Retrospective analysis of clinical data from patients with nonmetastatic high-grade osteosarcoma.
  • Comparison of DFS rates between single-agent and multiagent adjuvant chemotherapy regimens.

Related Experiment Videos

  • Evaluation of DFS in patients undergoing limb-salvage surgery versus amputation.

    • Main Results:

    • Multiagent, alternating adjuvant chemotherapy resulted in a significantly improved two-year DFS (78%) compared to single-agent chemotherapy (42% five-year DFS).
    • Patients undergoing limb-salvage surgery (49% of cases) showed comparable two-year DFS rates (69%) to amputees (72%).
    • Follow-up periods ranged from 0.6 to 13.8 years, providing robust data for survival analysis.

    Conclusions:

    • Alternating, multiagent adjuvant chemotherapy significantly enhances DFS in nonmetastatic high-grade osteosarcoma.
    • Limb-salvage surgery is a viable and safe alternative to amputation, with no increased risk of relapse.
    • These findings support the continued use of aggressive adjuvant chemotherapy and limb-sparing surgical techniques in osteosarcoma management.